Lenalidomide, rituximab, and methotrexate are effective in newly diagnosed primary central nervous system lymphoma
Xianggui Yuan,
Yaping Xie,
Nengwen Xu,
Hui Liu,
Panpan Chen,
Aiqi Zhao,
Yun Liang,
Wenbin Qian
Affiliations
Xianggui Yuan
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310009
Yaping Xie
Department of Hematology, the Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310006
Nengwen Xu
Department of Hematology, the Lishui Hospital, Zhejiang University School of Medicine, Lishui, China, 323000
Hui Liu
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310009
Panpan Chen
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310009
Aiqi Zhao
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310009
Yun Liang
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310009
Wenbin Qian
Department of Hematology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, 310009; National Clinical Research Center for Hematologic Diseases, the First Affiliated Hospital of Soochow University, Suzhou, China, 215123
